References
- St Croix B, Rago C, Velculescu V et al. Genes expressed in human tumor endothelium. Science289(5482), 1197–1202 (2000).
- Madden SL, Cook BP, Nacht M et al. Vascular gene expression in nonneoplastic and malignant brain. Am. J. Pathol.165(2), 601–608 (2004).
- Zhong X, Ran YL, Lou JN et al. Construction of human liver cancer vascular endothelium cDNA expression library and screening of the endothelium-associated antigen genes. World J. Gastroenterol.10(10), 1402–1408 (2004).
- Allinen M, Beroukhim R, Cai L et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell6(1), 17–32 (2004).
- Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A et al. Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biol. Ther.5(6), 635–642 (2006).
- Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A et al. Tumor vascular proteins as biomarkers in ovarian cancer. J. Clin. Oncol.25(7), 852–861 (2007)
- Macfadyen Jr, Haworth O, Roberston D et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Letts579(12), 2569–2575 (2005).
- Conejo-Garcia Jr, Buckanovich RJ, Benencia F et al. Vascular leukocytes contribute to tumor vascularization. Blood105(2), 679–681 (2005).
- Lu C, Bonome T, Li Y et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res.67(4), 1757–1768 (2007).
- Conejo-Garcia Jr, Benencia F, Courreges MC et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med.10(9), 950–958 (2004).
- Yang L, Debusk LM, Fukuda K et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell6(4), 409–421 (2004).
- De Palma M, Venneri MA, Galli R et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell8(3), 211–226 (2005).
- Venneri MA, DE Palma M, Ponzoni M et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood109(12), 5276–585 (2007).
- Edwards BK, Brown ML, Wingo PA et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J. Natl Cancer Inst.97(19), 1407–1427 (2005).
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med.1(1), 27–31 (1995).
- Bergers G, Brekken R, Mcmahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol.2(10), 737–744 (2000).
- Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br. J. Cancer90(11), 2053–2058 (2004).
- Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer4(1), 71–78 (2004).
- Wood GW, Neff JE, Stephens R. Relationship between monocytosis and T-lymphocyte function in human cancer. J. Natl Cancer Inst.63(3), 587–592 (1979).
- Normann SJ, Schardt M, Sorkin E. Cancer progression and monocyte inflammatory dysfunction: relationship to tumour excision and metastasis. Int. J. Cancer23(1), 110–113 (1979).
- Moldow RE. Monocytosis in malignancy. Ann. Intern. Med.74(3), 449 (1979).
- Barrett O Jr. Monocytosis in malignant disease. Ann. Intern. Med.73(6), 991–992 (1970).
- Elsheikh E, Uzunel M, He Z et al. Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity. Blood106(7), 2347–2355 (2005).
- Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med.348(3), 203–213 (2003).
- Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS111(11), 1011–1018 (2003).
- Wulfing P, Kersting C, TIO J et al. Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin. Cancer Res.10(7), 2393–2400 (2004).
- Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat.36(2), 169–180 (1995).
- Buckanovich RJ, Benencia F, Kim S et al. Endothelin (B) receptor mediates the endothelial barrier to T cell homing to tumors. Nat. Med. (2008) (In press).
- Monk BJ, Han E, Josephs-Cowan CA et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol.102(2), 140–144 (2006).
- Starling N, Cunningham D. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Curr. Opin. Oncol.16(4), 385–390 (2004).
- Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc.)39(Suppl. C), 1–16 (2003).
- Liao F, Doody JF, Overholser J et al. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res.62(9), 2567–2575 (2002).
- Jaggi JS, Henke E, Seshan SV et al. Selective α-particle mediated depletion of tumor vasculature with vascular normalization. PLoS ONE2(3), e267 (2007).
- Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res.61(21), 7846–7854 (2001).
- Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat.8(6), 381–402 (2005).
- Jung K-H, Lee K-H, Paik J-Y et al. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J. Nucl. Med.47(12), 2000–2007 (2006).
- Janssen ML, Oyen WJ, Dijkgraaf I et al. Tumor targeting with radiolabeled αVβ3 integrin binding peptides in a nude mouse model. Cancer Res.62(21), 6146–6151 (2002).
- Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl Acad. Sci. USA99(11), 7444–7449 (2002).
- Reddy GR, Bhojani MS, Mcconville P et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res.12(22), 6677–6686 (2006).
- Halin C, Rondini S, Nilsson F et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol.20(3), 264–269 (2002).
- Bak SP, Walters JJ, Takeya M, Conejo–Garcia JR, Berwin BL. Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res.67(10), 4783–4789 (2007).
- Chang SS, Reuter VE, Heston WD et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res.59(13), 3192–3198 (1999).
- Milowsky MI, Nanus DM, Kostakoglu L et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol.25(5), 540–547 (2007).
- Seaman S, Stevens J, Yang MY et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell11(6), 539–554 (2007).
- Coukos G, Conejo–Garcia JR, Buckanovich RJ, Benencia F. Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Adv. Exp. Med. Biol.590, 185–193 (2007).
- Glod J, Kobiler D, Noel M et al. Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood107(3), 940–946 (2006).
- Peters BA, Diaz LA, Polyak K et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med.11(3), 261–262 (2005).
- Teicher BA. New tumor vascular drug targets form human tumor endothelial cells: discovery and validation. Presented at: AACR Special Conference in Cancer Research. Anti-Angiogenesis and Drug Delivery to Tumors: Bench to Bedside and Back, Boston Mass, Nov. 9–13th (2005).